Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
Key Information
Due Date: December 20, 2024
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: $581,371
Funding Type: Grant
Match Required: No
Contact Info:
OERWebmaster03@od.nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
This description refers to the Catalyze: Product Definition grant for Small Molecules and Biologics. The goal of the grant is to support early-stage projects in the translational phase to detect and outline possible healing candidates for diseases and disorders involving the heart, lungs, blood, and sleep. This grant is an aspect of the broader Catalyze innovation initiative. It aims to push projects to a point where they become eligible for the NHLBI (National Heart, Lung, and Blood Institute) Catalyze Preclinical program. Alternatively, these projects can then garner standalone development aid from other federal bodies or private partners. The end aim is to facilitate the preclinical development and fine-tuning of therapeutic agents. This grant does not encompass clinical trials.
Show More
Key Dates
Open Date: January 24, 2022
Application Due Date: December 20, 2024
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses